SCOR Se

SCOR Se

SZCRF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$6.79B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
SCOR SeSCOR Se7.95.31%19%0.40.8

Earnings Call Q3 2026

October 30, 2026 - AI Summary

Strong operating delivery; ROE and solvency materially ahead - Q3 net income: EUR 206m; Q3 ROE: 20.4% (vs Forward 2026 target: 12%). - 1–9M net income: EUR 615m; annualized ROE: 19.3%. - Solvency II ratio: 221% (up +6pp vs year-end 2025) driven by elevated operating capital generation across activities. - Economic value growth (1–9M): +11.9% at constant economics, above Forward 2026 target of 9%. - Forecast/outlook: Management says SCOR is well positioned to meet targets entering the final quarter of the 3-year strategic plan, with teams focused on 1 Jan 2027 renewals.
P&C performance: resilient underwriting despite nat cats; attritional strength enables buffer building - Q3 combined ratio: 84.1% vs target 87%; nat cat ratio: 9.1% within budget. - Nat cat impact included Colombian earthquake plus European storms, fires in France, and flood in Bangkok; SCOR highlights its prudent nat cat reserving approach. - Attritional loss ratio: described as “excellent” / strong and still supports additional reserve buffer build. - Key investor takeaway: management believes the attritional run-rate remains robust and is sticky over time, helped by underwriting discipline and pricing adequacy (2025–26), while noting some lag from market hardening seen in 2023 moving through accounting results.
Life & Health: consistent “reset” performance; confidence remains for ongoing assumptions - Q3 insurance service result: EUR 119m, including positive experience variance of EUR 12m. - New business CSM in Life & Health: increasing year-on-year on both quarterly and 9-month bases; management credits portfolio evolution and mix. - Trend/incentives/opportunities: mix shifting toward protection + financial solutions + longevity (per management commentary on new business CSM mix). - Cash flow stance: Q3 Life & Health operating cash flow described as strong, but management stresses quarterly volatility and that Covea arbitration impact is small; SCOR expects neutral/positive Life & Health cash flow in 2026, but cautions this is not the same as holding-level distributable cash due to subsidiary structure.

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$6.79 Billion
Enterprise Value$7.98 Billion
Annual dividend$2.22
Dividend yield5.31%
Earnings per Share$4.76
Beta0.5
Outstanding Shares177,586,000

Return

Return on Equity18.50%ROE
Return on Assets2.17%
Return on Invested Capital2.50%

Valuation & Multiples

P/E Ratio7.87P/E Ratio
PEG-108.43PEG
Price to Sales0.42Price to Sales
Price to Book Ratio1.59Price to Book Ratio
Enterprise Value to Revenue0.48
Enterprise Value to EBIT8.57
Enterprise Value to Net Income9
Total Debt to Enterprise0.41
Debt to Equity0.75Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 30, 2026
EPS
$1.31
Est. $1.05
Revenue
$4.26 B
Est. $4.20 B

Next Earnings Call

Expected Date
March 10, 2027
EPS Estimate
$1.12
Consensus analyst estimate
Revenue Estimate
$4.21 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About SCOR Se

3,610 employees
CEO: Thierry Leger

SCOR SE is a prominent global player specializing in life and property & casualty (P&C) reinsurance. The company extends its comprehensive coverage to diverse markets spanning Europe, the Middle East, Africa, the Americas (including Lati...